Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADVM
stocks logo

ADVM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.722
-12.14%
--
--
-0.940
-58.22%
--
--
-0.927
-60.4%
Estimates Revision
The market is revising No Change the revenue expectations for Adverum Biotechnologies, Inc. (ADVM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 18.47%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.72%
In Past 3 Month
Stock Price
Go Up
up Image
+18.47%
In Past 3 Month
Wall Street analysts forecast ADVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADVM is 4.90 USD with a low forecast of 4.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ADVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADVM is 4.90 USD with a low forecast of 4.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 4.170
sliders
Low
4.00
Averages
4.90
High
5.50
Current: 4.170
sliders
Low
4.00
Averages
4.90
High
5.50
H.C. Wainwright
Matthew Caufield
Buy -> Neutral
downgrade
$30 -> $5
2025-11-17
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$30 -> $5
2025-11-17
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Matthew Caufield downgraded Adverum Biotechnologies to Neutral from Buy with a price target of $5, down from $30, after the company entered into an agreement to be acquired by Eli Lilly (LLY).
Mizuho
Outperform -> NULL
downgrade
$12
2025-10-29
Reason
Mizuho
Price Target
$12
2025-10-29
downgrade
Outperform -> NULL
Reason
Mizuho lowered the firm's price target on Adverum Biotechnologies to $5.50 from $12 and keeps an Outperform rating on the shares.
RBC Capital
Sector Perform
maintain
$3 -> $4
2025-10-28
Reason
RBC Capital
Price Target
$3 -> $4
2025-10-28
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Adverum Biotechnologies (ADVM) to $4 from $3 and keeps a Sector Perform rating on the shares. The firm cites the company's acquisition announcement by Eli Lilly (LLY) at $3.56 per share in cash plus 1 nontransferable CVR valued up to $8.91/share contingent upon achievement of two milestone events, the analyst tells investors in a research note.
Chardan
Chardan
Buy
to
Neutral
downgrade
$5
2025-10-24
Reason
Chardan
Chardan
Price Target
$5
2025-10-24
downgrade
Buy
to
Neutral
Reason
Chardan downgraded Adverum Biotechnologies (ADVM) to Neutral from Buy with a $5 price target after the company agreed to be acquired by Eli Lilly (LLY) for $3.56 per share in cash plus a non-transferrable contingent value right worth up to $8.91 in cash pending certain milestones. The firm is "disappointed" with the deal as it believes the price paid "significantly undervalues" Adverum. However, it acknowledges that the company was "rapidly approaching the end of its cash runway."
Truist
Joon Lee
Buy
to
Hold
downgrade
$5
2025-10-24
Reason
Truist
Joon Lee
Price Target
$5
2025-10-24
downgrade
Buy
to
Hold
Reason
Truist analyst Joon Lee downgraded Adverum Biotechnologies (ADVM) to Hold from Buy with a $5 price target after Eli Lilly (LLY) agreed to acquire Adverum for $3.56 per share in cash upfront and a $8.91 CVR for a total per share consideration of up to $12.47. The deal "undervalues ixo-vec in our view," but given the company's limited operational runway, the firm views it as "a good outcome," the analyst tells investors.
Chardan
Chardan
Buy
to
Neutral
downgrade
$5
2025-10-24
Reason
Chardan
Chardan
Price Target
$5
2025-10-24
downgrade
Buy
to
Neutral
Reason
Chardan downgraded Adverum Biotechnologies (ADVM) to Neutral from Buy with a $5 price target after the company agreed to be acquired by Eli Lilly (LLY) for $3.56 per share in cash plus a non-transferrable contingent value right worth up to $8.91 in cash pending certain milestones. The firm is "disappointed" with the deal as it believes the price paid "significantly undervalues" Adverum. However, it acknowledges that the company was "rapidly approaching the end of its cash runway."
See All Ratings

Valuation Metrics

The current forward P/E ratio for Adverum Biotechnologies Inc (ADVM.O) is -0.92, compared to its 5-year average forward P/E of -3.97. For a more detailed relative valuation and DCF analysis to assess Adverum Biotechnologies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.97
Current PE
-0.92
Overvalued PE
5.33
Undervalued PE
-13.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.01
Undervalued EV/EBITDA
-2.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
291.35
Current PS
0.00
Overvalued PS
1004.91
Undervalued PS
-422.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 9153.78% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 9153.78% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ADVM News & Events

Events Timeline

(ET)
2025-12-01
07:30:00
Adverum to be Acquired by Eli Lilly at $3.56 per Share
select
2025-10-24 (ET)
2025-10-24
08:34:07
Eli Lilly set to purchase Adverum Biotechnologies at a price of up to $12.47 per share
select
2025-09-22 (ET)
2025-09-22
08:17:59
Adverum announces the conclusion of participant screening for the Phase 3 ARTEMIS trial.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-01Newsfilter
Adverum Biotechnologies to be Acquired by Eli Lilly for Up to $12.47 per Share
  • Acquisition Offer: Eli Lilly initiated a tender offer for Adverum on November 7, 2025, providing $3.56 per share in cash plus up to $8.91 in contingent value rights, totaling a potential $12.47 per share, significantly enhancing shareholder value.
  • Funding Support: The Promissory Note signed with Lilly allows Adverum to access up to $65 million, of which $40 million has already been advanced, with an additional $25 million expected on December 5, 2025, to support clinical trials and operations.
  • Liquidity Risk: Should the merger agreement be terminated, Adverum faces a liquidity crisis, unable to repay the Promissory Note, which could lead to bankruptcy, highlighting the urgency of this transaction.
  • Board Recommendation: After an 18-month strategic review, Adverum's Board believes the transaction with Lilly is the best option, especially given the absence of other acquisition proposals, ensuring immediate liquidity and value for shareholders.
[object Object]
Preview
9.0
11-20NASDAQ.COM
Eli Lilly's Growing Drug Portfolio Boosts Sales Beyond GLP-1

  • Eli Lilly's Stock Performance: Eli Lilly's stock reached over $1000 per share for the first time, driven by the success of its GLP-1 drugs, Mounjaro and Zepbound, and is approaching a $1 trillion market cap.

  • New Drug Approvals and Revenue Growth: The company has gained approvals for several new drugs, including Omvoh and Jaypirca, contributing significantly to revenue growth, with expectations for continued sales increases from these products in 2026.

  • M&A Strategy for Long-Term Growth: To diversify its portfolio beyond GLP-1 drugs, Lilly is pursuing mergers and acquisitions, including the recent agreement to acquire Adverum Biotechnologies, which will enhance its pipeline with gene therapies.

  • Competitive Landscape and Valuation: While Lilly's stock has outperformed the industry, it is considered expensive based on its price/earnings ratio, and analysts have raised earnings estimates for 2025 and 2026, indicating positive market sentiment.

[object Object]
Preview
7.0
11-20PRnewswire
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

  • Investigation of Companies: Halper Sadeh LLC is investigating Barinthus Biotherapeutics, Fifth Third Bancorp, Adverum Biotechnologies, and Huntington Bancshares for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their mergers and acquisitions.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to learn about their legal rights and options, as there may be limited time to enforce these rights.

  • Compensation Structure: The law firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

  • Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover funds and implement corporate reforms.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Adverum Biotechnologies Inc (ADVM) stock price today?

The current price of ADVM is 4.17 USD — it has increased 0 % in the last trading day.

arrow icon

What is Adverum Biotechnologies Inc (ADVM)'s business?

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. It discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

arrow icon

What is the price predicton of ADVM Stock?

Wall Street analysts forecast ADVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADVM is 4.90 USD with a low forecast of 4.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Adverum Biotechnologies Inc (ADVM)'s revenue for the last quarter?

Adverum Biotechnologies Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Adverum Biotechnologies Inc (ADVM)'s earnings per share (EPS) for the last quarter?

Adverum Biotechnologies Inc. EPS for the last quarter amounts to -2.03 USD, increased 30.97 % YoY.

arrow icon

What changes have occurred in the market's expectations for Adverum Biotechnologies Inc (ADVM)'s fundamentals?

The market is revising No Change the revenue expectations for Adverum Biotechnologies, Inc. (ADVM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 18.47%.
arrow icon

How many employees does Adverum Biotechnologies Inc (ADVM). have?

Adverum Biotechnologies Inc (ADVM) has 155 emplpoyees as of December 05 2025.

arrow icon

What is Adverum Biotechnologies Inc (ADVM) market cap?

Today ADVM has the market capitalization of 92.06M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free